Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

Myocardial Ischemia Clinical Trial

Official title:

Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01372891
• Other study ID #: xjyy110502
• Status: Recruiting
• Phase: N/A
• First received: June 10, 2011
• Last updated: November 21, 2011
• Start date: April 2010
• Est. completion date: December 2014

Study information

• Verified date: November 2011
• Source: Xijing Hospital
• Contact: Ling Tao, M.D Ph.D
• Phone: +86-15002955798
• Email: lingtao2006[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Description:

Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 2014
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• All patients > 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.

Exclusion Criteria:

• The end-stage renal failure

• The patients who are relieving dialysis

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Kidney Diseases
• Myocardial Ischemia

Locations

Country	Name	City	State
China	Xijing Hospital	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline	samples will be collected at 24, 48 and 72 hours after PCI	3 days	No
Secondary	a 25% increase in SCr from baseline	samples will be collected at 24, 48 and 72 hours after PCI.	3 days	No